Mapp Biopharmaceutical, Inc.
Mapp Biopharmaceutical, Inc. is a US-based biotechnology company focused on developing monoclonal antibody therapeutics for the prevention and treatment of infectious diseases with an emphasis on addressing unmet needs in global health and biodefense. Founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin, the company pursues treatments for high-priority pathogens, including ebolaviruses, Marburg virus, Nipah virus, and other threats such as hantavirus and ricin. Mapp advances candidates through preclinical and clinical evaluation, often in partnership with government and academic entities.
Industries
N/A
Mapp Biopharmaceutical, Inc.
Patents
Anti-respiratory syncytial virus antibodies, methods of their generation and use
2026-05-19 • US-12630611-B2
View DetailsAnti-respiratory syncytial virus antibodies, methods of their generation and use
2023-08-15 • US-11725045-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-08-09 • US-11407817-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-08-09 • US-11407816-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-02-22 • US-11254732-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-02-08 • US-11242378-B2
View Details
Anti-respiratory syncytial virus antibodies, methods of their generation and use
2026-05-19 • US-12630611-B2
View DetailsAnti-respiratory syncytial virus antibodies, methods of their generation and use
2023-08-15 • US-11725045-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-08-09 • US-11407817-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-08-09 • US-11407816-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-02-22 • US-11254732-B2
View DetailsMonoclonal antibodies and cocktails for treatment of Ebola infections
2022-02-08 • US-11242378-B2
View DetailsProducts
A monoclonal antibody developed for immediate protection and post-exposure use against Nipah virus, currently in human clinical trials.
A single human monoclonal antibody developed for treatment and post-exposure prophylaxis against Marburg and Ravn viruses.
A combination of two monoclonal antibodies targeting multiple ebolavirus species for treatment and post-exposure prophylaxis.
Therapeutic antibody product under advanced development and potential procurement contract for Sudan ebolavirus.
A monoclonal antibody product in development to counteract botulinum neurotoxin exposure.
A monoclonal antibody developed for immediate protection and post-exposure use against Nipah virus, currently in human clinical trials.
A single human monoclonal antibody developed for treatment and post-exposure prophylaxis against Marburg and Ravn viruses.
A combination of two monoclonal antibodies targeting multiple ebolavirus species for treatment and post-exposure prophylaxis.
Therapeutic antibody product under advanced development and potential procurement contract for Sudan ebolavirus.
A monoclonal antibody product in development to counteract botulinum neurotoxin exposure.
Expertise Areas
- Monoclonal antibody therapeutics
- Infectious disease countermeasures
- Biodefense product development
- Plant-based biomanufacturing
Key Technologies
- Monoclonal antibody engineering
- Plant-based transient expression systems
- CHO cell protein expression
- Preclinical animal efficacy models
Key People
President
CEO
President
CEO
News & Updates
Study demonstrating the use of a cross-reactive monoclonal antibody to protect nonhuman primates against Nipah virus.
Preclinical study evaluating antibody prophylaxis for Marburg virus in nonhuman primates.
Investigation of the efficacy of a humanized monoclonal antibody for Argentine hemorrhagic fever in nonhuman primates.
Announcement of upcoming human clinical trials for a novel monoclonal antibody against Nipah virus in India and Bangladesh.
BARDA collaborates to advance the development of a therapeutic for Marburg virus disease.
ASPR announces a contract for the advanced development and potential purchase of a monoclonal antibody therapeutic for Sudan ebolavirus.
Study demonstrating the use of a cross-reactive monoclonal antibody to protect nonhuman primates against Nipah virus.
Preclinical study evaluating antibody prophylaxis for Marburg virus in nonhuman primates.
Investigation of the efficacy of a humanized monoclonal antibody for Argentine hemorrhagic fever in nonhuman primates.
Announcement of upcoming human clinical trials for a novel monoclonal antibody against Nipah virus in India and Bangladesh.
BARDA collaborates to advance the development of a therapeutic for Marburg virus disease.
ASPR announces a contract for the advanced development and potential purchase of a monoclonal antibody therapeutic for Sudan ebolavirus.